Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
255 hedge funds and large institutions have $949M invested in Catalyst Pharmaceutical in 2023 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 79 increasing their positions, 91 reducing their positions, and 25 closing their positions.
104% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $694K
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
3% more funds holding
Funds holding: 248 → 255 (+7)
2.17% less ownership
Funds ownership: 77.68% → 75.51% (-2.2%)
13% less repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 91
14% less capital invested
Capital invested by funds: $1.11B → $949M (-$159M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$16.1M |
| 2 |
RA
Royce & Associates
New York
|
+$7.65M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$6.77M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$4.68M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$25.2M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.4M |
| 3 |
Man Group
London,
United Kingdom
|
-$11.2M |
| 4 |
Two Sigma Advisers
New York
|
-$8.51M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$6.86M |
CPRX Hedge Fund Activity: Q3 2023 in Review
255 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2023, worth a combined $949M — down 14% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CPRX positions and 25 closed out — a net gain of 9 holders — while 79 added to existing stakes and 91 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $16.1M. The largest seller was State Street, cutting an estimated $25.2M.
- 255 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2023, up from 248 in Q2 2023.
- Funds reported $949M of Catalyst Pharmaceutical stock for Q3 2023, down 14% quarter-over-quarter.
- 34 funds opened new Catalyst Pharmaceutical positions in Q3 2023 and 25 closed out, a net change of +9 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2023 was Opaleye Management, an estimated $16.1M added.
- The largest Catalyst Pharmaceutical seller in Q3 2023 was State Street, an estimated $25.2M sold.
Based on aggregated 13F filings for Q3 2023.